{"paper_id":"3c296d97-4ec0-4e63-af42-dacac4568d64","body_text":"Article title: Progestins - a review of clinical application in gynecology\nAuthors: Dominika Żyła, Dominika Kuźmiuk, Martyna Rynkowska, Małgorzata Satora, Krzysztof Kułak and Rafał Tarkowski\nJournal: Annals of Medicine\nBibliometrics: Volume 57, Number 01, 2570794\nDOI: https://doi.org/10.1080/07853890.2025.2570794\nWhen the above article was first published online, two references were inadvertently merged into a single reference entry. This has now been corrected, and the article has been republished. The details of the correction are provided below.\nReference correction\nReference 174 was previously presented as a combined entry. It has now been split into two separate references, and all subsequent references have been renumbered accordingly.\nPreviously published as:\n174. Powell SG, Sharma P, Masterson S, Wyatt J, Arshad I, Ahmed S, Lash G, Cross M, Hapangama DK. Vascularisation in deep endometriosis: a systematic review with narrative outcomes. Cells. 2023 12(9):1318.; Yeh YT, Chang CW, Wei RJ, Wang SN. Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects. Biomed Res Int. 2013;2013:290575. doi:10.1155/2013/290575. doi:10.3390/cells12091318.\nCorrected to:\n174. Powell SG, Sharma P, Masterson S, Wyatt J, Arshad I, Ahmed S, Lash G, Cross M, Hapangama DK. Vascularisation in deep endometriosis: a systematic review with narrative outcomes. Cells. 2023;12(9):1318. doi:10.3390/cells12091318.\n175. Yeh YT, Chang CW, Wei RJ, Wang SN. Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects. Biomed Res Int. 2013;2013:290575. doi:10.1155/2013/290575.\nCitation correction\nIn the following sentence, the citation range has been updated to reflect the renumbering:\nPreviously published as:\n“They may be an effective therapeutic option for patients with advanced, recurrent endometrial cancer (with low toxicity and positive P4 receptor), as well as in the treatment of deep endometriosis [168–174].”\nCorrected to:\n“They may be an effective therapeutic option for patients with advanced, recurrent endometrial cancer (with low toxicity and positive P4 receptor), as well as in the treatment of deep endometriosis [168–175].”\nAll subsequent citations have been renumbered accordingly.","source_license":"CC-BY-4.0","license_restricted":false}